FDA – Industry MDUFA V Reauthorization Meeting February 3, 2022, 1:00 pm - 1:18 pm EST

Virtual Via Zoom

Purpose

To discuss MDUFA V reauthorization.

Attendees

FDA

- Lauren Roth, OC OP
- Sara Aguel, CDRH
- Cherron Blakely, CDRH
- Kathryn Capanna, CDRH
- Josh Chetta, CDRH
- Misti Malone, CDRH
- Jonathan Sauers, CDRH
- Suzanne Schwartz, CDRH
- Don St. Pierre, CDRH
- Michelle Tarver, CDRH
- Eli Tomar, *CDRH*

Cherie Ward-Peralta, CBER

Barbara Zimmerman, CDRH

- Angela Granum, CBER
- Diane Goyette, ORA
- Claire Davies, OCC
- Louise Howe, OCC
- Malcolm Bertoni, Consultant
- Nia Benjamin, CDRH
- Sharon Davis, CDRH
- Marta Gozzi, CDRH
- Ellen Olson, CDRH

Industry

AdvaMed Team

- Janet Trunzo, AdvaMed
- Zach Rothstein, AdvaMed
- Nathan Brown, Akin Gump
- Phil Desjardins, Johnson & Johnson
- Michael Pfleger, Alcon
- Nicole Taylor Smith, *Medtronic*

MITA Team

- Peter Weems, MITA
- Diane Wurzburger, GE Healthcare
- Nicole Zuk. Siemens Healthineers

MDMA Team

- Mark Leahey, MDMA
- Mark Gordon, Alcon
- Melanie Raska, Boston Scientific
- Elizabeth Sharp, Cook Group

ACLA Team

- Thomas Sparkman, ACLA
- Don Horton, *Labcorp*
- Shannon Bennett, Mayo Clinic Laboratories
- Amy Leiser, Covington & Burling

Meeting Start Time: 1:00 pm EST

Executive Summary

During the February 3, 2022 user fee negotiation meeting, FDA and Industry agreed to resume a regular cadence of negotiation meetings to reach agreement on a proposed MDUFA V commitment letter as quickly as possible. The parties scheduled future negotiation meetings for the following weeks.

Meeting End Time: 1:18 pm EST